Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
If you purchased Disc Medicine securities and would like to join the prospective action, please click “Join This Class Action.”
On February 13, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine’s new drug application (“NDA”) as there were uncertainties in the NDA that would need additional evidence.
On this news, Disc Medicine’s stock price fell 22% on February 13, 2026.
The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.
Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.
Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.
The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.
